

QEEG Clinical Report

EEGLens



The QEEG report is provided by NPCindex Institute, operating under the QEEGhome brand.

Personal Data:

Name: Test Test
Gender: Male
Age: 1995-08-15 - 30.5
Handedness: Right

Clinical Data:


Initial diagnosis: Drug Abuse
Medication: -
Date of Recording: 2025-12-23
Source of Referral: Drtest

This case belongs to Drtest


EEG Quality



Z-score Information



TMS Responsibility




EEG Neuromarker Values

Neuromarker	Region	Value	Assessment
APF - EO	Frontal	11.17	High
APF - EC	Frontal	11.00	High
APF - EO	Occipital	11.25	High
APF - EC	Occipital	11.00	High
Arousal Level - EO	-	-	Normal
Arousal Level - EC	-	-	Normal

Denoising Information

Eye Close

Raw EEG



Rejected Channel



Total Recording Time Remaining:

218.58 sec

Number of Eye and Muscle Elements

Eye: 1

Muscle: 0

Low Artifact Percentage



High Artifact Percentage




Total Artifact Percentage



EEG Quality: perfect

Denoised EEG




Flat Channel



Eye Open

Raw EEG



Rejected Channel



Total Recording Time Remaining:

240.14 sec

Number of Eye and Muscle Elements

Eye: 2

Muscle: 1

Low Artifact Percentage



High Artifact Percentage




Total Artifact Percentage



EEG Quality: perfect

Denoised EEG




Flat Channel




Pathological Assessment for Substance Abuse


Comorbid Symptoms



Relapse Index




Substance Abuse Compatibility




Functional Problems Source Detection

Eye Close



Eye Open





Note

The **Relapse** graph displays the relapse index based on a combination of EEG neuromarkers. It is valid only if the patient has used each of the substances included in the chart; otherwise, the index is not applicable.

The **Compatibility** graph shows how closely the patient's EEG neuromarkers match typical EEG changes caused by specific substances. It helps identify the dominant substance effect in cases of multiple drug use. This index is also valid only if the patient has actually used the substances represented.

QEEG Based Predicting Medication Response



Explanation

These two tables present the primary neuromarker findings from NPCindex Research Institute, derived from our research on medication-free Iranian cohorts.

The NPCindex team identified and validated 85 candidate features across raw bands, spectra, power, coherence, and LORETA, and report them here without sub-segregation to minimize complexity.

For context and methodology, see qeeghome.com.



Medication Recommendation

Use the medication charts in three quick steps:

- 1- Filter the medication groups by your working diagnosis.
- 2- Within each group, re-filter by your clinical assessment and the patient's specifics (comorbidities, contraindications, preferences).
- 3- From the remaining options, use the reported effect sizes to choose.

Based on papers, following this workflow has raised our response rates by ~20-30%.


Vigilance




EEG Neuromarker Values

Neuromarker	Region	Value	Assessment
APF - EO	Frontal	11.17	High
APF - EC	Frontal	11.00	High
APF - EO	Occipital	11.25	High
APF - EC	Occipital	11.00	High
Alpha Asymmetry	Frontal	00.05	Anxiety
Alpha Asymmetry	Occipital	00.04	Anxiety
Beta Asymmetry	Frontal	00.05	Anhedonia
Alpha Blocking Error	-	-	Not
Vigilance Level - EO	-	06.00	Normal
Vigilance Level - EC	-	02.00	Normal
Vigilance Mean - EO	-	05.92	Normal
Vigilance Mean - EC	-	01.89	Low
Vigilance Regulation - EO	-	00.02	Normal
Vigilance Regulation - EC	-	00.36	Normal
Vigilance 0 Stage (%) - EO	-	95.87	Normal
Vigilance 0 Stage (%) - EC	-	00.00	Normal
Vigilance A1 Stage (%) - EO	-	00.00	-
Vigilance A1 Stage (%) - EC	-	00.46	-

RDoC Domain




EEG Spectra




Z Score Summary Information

Eye Close




Eye Open



Theta/Beta Ratio

Eye Close



Eye Open

